tetano
Editor, Senior Moderator
Nanomedicine. 2015 Mar 6. pii: S1549-9634(15)00054-4. doi: 10.1016/j.nano.2015.02.008. [Epub ahead of print]
[h=1]Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.[/h] Patel JM[SUP]1[/SUP], Kim MC[SUP]2[/SUP], Vartabedian VF[SUP]1[/SUP], Lee YN[SUP]3[/SUP], He S[SUP]1[/SUP], Song JM[SUP]4[/SUP], Choi HJ[SUP]5[/SUP], Yamanaka S[SUP]1[/SUP], Amaram N[SUP]1[/SUP], Lukacher A[SUP]1[/SUP], Montemagno C[SUP]5[/SUP], Compans RW[SUP]6[/SUP], Kang SM[SUP]3[/SUP], Selvaraj P[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recombinant virus-like nanoparticles (VLPs) are a promising nanoparticle platform to develop safe vaccines for many viruses. Herein, we describe a novel and rapid protein transfer process to enhance the potency of enveloped VLPs by decorating influenza VLPs with exogenously added glycosylphosphatidylinositol-anchored immunostimulatory molecules (GPI-ISMs). With protein transfer, the level of GPI-ISM incorporation onto VLPs is controllable by varying incubation time and concentration of GPI-ISMs added. ISM incorporation was dependent upon the presence of a GPI-anchor and incorporated proteins were stable and functional for at least 4 weeks when stored at 4?C. Vaccinating mice with GPI-granulocyte macrophage colony-stimulating factor (GM-CSF)-incorporated-VLPs induced stronger antibody responses and better protection against a heterologous influenza virus challenge than unmodified VLPs. Thus, VLPs can be enriched with ISMs by protein transfer to increase the potency and breadth of the immune response, which has implications in developing effective nanoparticle-based vaccines against a broad spectrum of enveloped viruses.
Copyright ? 2015. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] GM-CSF; GPI-anchored proteins; Influenza; Virus-like particles; protein transfer
PMID: 25752855 [PubMed - as supplied by publisher]
[h=1]Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses.[/h] Patel JM[SUP]1[/SUP], Kim MC[SUP]2[/SUP], Vartabedian VF[SUP]1[/SUP], Lee YN[SUP]3[/SUP], He S[SUP]1[/SUP], Song JM[SUP]4[/SUP], Choi HJ[SUP]5[/SUP], Yamanaka S[SUP]1[/SUP], Amaram N[SUP]1[/SUP], Lukacher A[SUP]1[/SUP], Montemagno C[SUP]5[/SUP], Compans RW[SUP]6[/SUP], Kang SM[SUP]3[/SUP], Selvaraj P[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recombinant virus-like nanoparticles (VLPs) are a promising nanoparticle platform to develop safe vaccines for many viruses. Herein, we describe a novel and rapid protein transfer process to enhance the potency of enveloped VLPs by decorating influenza VLPs with exogenously added glycosylphosphatidylinositol-anchored immunostimulatory molecules (GPI-ISMs). With protein transfer, the level of GPI-ISM incorporation onto VLPs is controllable by varying incubation time and concentration of GPI-ISMs added. ISM incorporation was dependent upon the presence of a GPI-anchor and incorporated proteins were stable and functional for at least 4 weeks when stored at 4?C. Vaccinating mice with GPI-granulocyte macrophage colony-stimulating factor (GM-CSF)-incorporated-VLPs induced stronger antibody responses and better protection against a heterologous influenza virus challenge than unmodified VLPs. Thus, VLPs can be enriched with ISMs by protein transfer to increase the potency and breadth of the immune response, which has implications in developing effective nanoparticle-based vaccines against a broad spectrum of enveloped viruses.
Copyright ? 2015. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] GM-CSF; GPI-anchored proteins; Influenza; Virus-like particles; protein transfer
PMID: 25752855 [PubMed - as supplied by publisher]